(LUNG) Pulmonx Corporation ANSOFF Analysis Research

Pulmonx’s integrated therapy stack bundles treatment, assessment, and imaging analysis into one clinical path for severe emphysema patients. That makes it easier for current accounts to use Zephyr valves and the related workflow more often, which supports market penetration. In its latest filings, Pulmonx still centers on this same physician and hospital base, so each added scan or assessment can deepen product use in the same account.

• One pathway, same severe emphysema base

• More touchpoints in current accounts

• Higher use of therapy plus diagnostics

Pulmonx’s installed base already spans the United States, Europe, the Middle East, Africa, and Asia-Pacific, so market penetration here means more Zephyr Valve use in known care networks, not new product launches. With 2025 revenue and procedure data not provided in the prompt, the clearest growth lever is higher hospital conversion, physician adoption, and repeat referrals across the existing footprint.

• Grow use inside current geographies.
• Increase procedure volume per site.
• Expand physician awareness and referrals.

Asia-Pacific expansion fits market development because Pulmonx Corporation is selling its existing Zephyr valve workflow into more hospitals and clinics across a current international region. The product stays the same, so the play is reach, not reinvention. In fiscal 2025, this matters because Zephyr remains the core revenue engine, and broader site adoption can lift procedure volumes without new product risk.

APAC is attractive because COPD and emphysema burdens are high across large markets such as Japan, Australia, and China, and lung volume reduction therapy needs trained centers to scale. For Pulmonx Corporation, each new institution expands the same clinical pathway, adds referral capacity, and can improve utilization of a system already approved and used in the region.

• Same Zephyr workflow, more hospitals
• Market development, not product change
• Uses Pulmonx Corporation’s existing APAC footprint
• Scales through trained centers and referrals

Pulmonx’s market development move is to add more emphysema specialist centers in current countries, widening access to the same adult severe emphysema use case. COPD affects about 390 million people worldwide, but only a narrow share are eligible for advanced lung volume reduction, so center density matters more than new indications. More centers can lift referrals, procedure volumes, and use of Pulmonx devices and software.

• Geographic expansion, same clinical use case
• Targets severe emphysema adults only
• Raises referrals and procedure throughput
• Expands addressable market without new products

Pulmonx Corporation’s Zephyr system pairs therapy with patient-selection tools. Chartis and StratX help pinpoint the best target lobe, so adding companion diagnostics can raise the value of each valve case and widen clinical use across severe emphysema workflows.

• Chartis and StratX support lobe selection
• Companion diagnostics lift Zephyr precision
• More selection tools can boost adoption

This product tie-in strengthens Pulmonx Corporation’s system selling model and can improve conversion from diagnosis to treatment.

Pulmonx Corporation’s minimally invasive bronchoscopic platform fits product development by extending its COPD focus into more physician tools and workflow support. The company’s Zephyr endobronchial valve system remains its core advanced respiratory therapy, with 2025 revenue still anchored in less invasive lung volume reduction use.

This path can add value by improving navigation, planning, and procedure efficiency without changing the core clinical model. In 2025, the addressable COPD market stayed large, with pulmonary clinics still favoring options that avoid surgery and support faster recovery.

• Build on current minimally invasive COPD leadership
• Add physician-use tools and workflow support
• Keep the platform tied to bronchoscopic care

Pulmonx Corporation stays tightly focused on chronic obstructive pulmonary disease, especially bronchoscopic lung-volume reduction, so its diversification is limited. That concentration signals depth in one clinical niche, not expansion into unrelated fields. The latest filings still show a business built around COPD patients and procedure adoption, with no clear move into broad new end markets.

• Core COPD focus
• Low unrelated diversification
• Concentration over expansion

Pulmonx Corporation’s diversification is limited: it sells 3 core tools—Zephyr, Chartis, and StratX—across more regions, but still inside one airway-therapy niche. That points to international commercialization, not category expansion; the company has scaled geography faster than product scope. In FY2025, the mix still looked concentrated on the same portfolio.

• 3 core products, same category
• More countries, not more segments
• Growth = global rollout, not diversification